1. Biopharmaceutical industry perspectives on the business prospects for personalized medicine. (September 2011) Authors: Milne, Christopher-Paul; Zuckerman, Rachael Journal: Personalized medicine Issue: Volume 8:Number 5(2011) Page Start: 541 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Can translational medicine bring us out of the R&D wilderness?. (September 2009) Authors: Milne, Christopher-Paul Journal: Personalized medicine Issue: Volume 6:Number 5(2009) Page Start: 543 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Complementary versus companion diagnostics: apples and oranges?. (January 2015) Authors: Milne, Christopher-Paul; Bryan, Crystal; Garafalo, Steven; McKiernan, Marie Journal: Biomarkers in medicine Issue: Volume 9:Number 1(2015) Page Start: 25 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Fixing the paradigm for biopharmaceutical R&D: Where to start?. (20th November 2008) Authors: Milne, Christopher-Paul Journal: International journal of biotechnology Issue: Volume 10:Number 5(2008) Page Start: 404 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Impact of Regulatory Incentive Programs on the Future of Pediatric Drug Development. (September 2019) Authors: Yen, Elizabeth; Davis, Jonathan M.; Milne, Christopher-Paul Journal: Therapeutic innovation & regulatory science Issue: Volume 53:Number 5(2019:Sep.) Page Start: 609 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Is the increasing cost of treating rare diseases sustainable?. (October 2013) Authors: Cohen, Joshua; Milne, Christopher-Paul Journal: Expert opinion on orphan drugs Issue: Volume 1:Number 8(2013:Aug.) Page Start: 581 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Prospects for Harmonizing Regulatory Science Programs in Europe, Japan, and the United States to Advance Regenerative Medicine. (November 2016) Authors: Milne, Christopher-Paul; Mittra, James; Kojima, Naoko; Sugiyama, Daisuke; Awatin, Josephine; Simmons, Gabrielle Journal: Therapeutic innovation & regulatory science Issue: Volume 50:Number 6(2016:Nov.) Page Start: 724 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Public- and Private-Sector Contributions to the Research and Development of the Most Transformational Drugs in the Past 25 Years: From Theory to Therapy. (November 2016) Authors: Chakravarthy, Ranjana; Cotter, Kristina; DiMasi, Joseph; Milne, Christopher-Paul; Wendel, Nils Journal: Therapeutic innovation & regulatory science Issue: Volume 50:Number 6(2016:Nov.) Page Start: 759 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. State of the industry for drug–diagnostic development: challenge and change on the path to precision medicine. (July 2016) Authors: Milne, Christopher-Paul; Cohen, Joshua; Chakravarthy, Ranjana; Awatin, Josephine Journal: Personalized medicine Issue: Volume 13:Number 4(2016) Page Start: 337 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Translational medicine : the future of therapy? /: the future of therapy?. (2013) Other Names: Mittra, James; Milne, Christopher-Paul Record Type: Book Extent: 1 online resource (xiv, 273 pages :), illustrations View Content: Available online (eLD content is only available in our Reading Rooms) ↗